Quintiles Library

Harnessing Vital Data Image
Featured White Paper

Harnessing vital data to inform an optimal market access strategy in the UK
Market access now demands closer collaboration between biopharma, payers and providers. In a climate where ongoing reimbursement of a drug relies on biopharma’s ability to demonstrate how it delivers value to the entire healthcare system, partnership working is essential. Outcomes audits should be seen as one of the most important tools available to biopharma. They deliver detailed action plans to both biopharma and the NHS, proposing improvements to the care pathway...
Show Filters
Fact Sheet
Generating the evidence you need to demonstrate the value stakeholders demand in the real...
Read More
Fact Sheet
セントラル・ラボラトリーサービス - 高品質のラボデータをタイムリーに:冊子 今日の薬剤開発環境のニーズを満たすには柔軟性が必要です。長期的視点でのセントラル・ラボサービスのパートナーが必要な場合、豊富な経験・知識を有し、世界各地にてサービスの提供が可能なセントラル・ラボが必須となります。 クインタイルズでは、アメリカ大陸、ヨーロッパ、アジア、アフリカの各地域に自社のセントラルラボ(QLAB)を所有し、安全性項目検査のみでなくバイオ分析、ADME、ゲノミクス等の様々なセントラルサービスをグローバルに展開しています。 これまでの経験や蓄積した知識を活用し、お客様のプロジェクトに最適なソリューションの提供が可能です。...
Read More
Brochure
Improve your probability of success:冊子 より健康な世界を創造するには、業界最高の発想と資源が必要です。 また、今まで考えられなかった協働も要求されます。 From pipeline to portfolio to population health™ (パイプラインからポートフォリオさらに人々の健康に至るまで)、バイオファーマとライフサイエンスのソリューションを実現する完全統合型アプローチを思い描いてください。 クインタイルズでは、より良い結果に向けて優れた情報提供力で見識を結集し、お客様の目標実現のために全力を尽くします。                      ...
Read More
Press Release
RESEARCH TRIANGLE PARK, NC – February 27, 2015 – Quintiles CEO Tom Pike will present at the 2015 Barclays Global Healthcare Conference on Tuesday, March 10, 2015 in Miami at the Loews Miami Hotel. The Quintiles presentation will begin at 11:15 a.m. (EST). Investors may access a live audio webcast of the presentation on the Quintiles Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100...
Read More
White Paper
This white paper outlines four best practices to increase probability of success: 1) Understanding patient motivators at each stage of the diabetes journey; 2) Designing the protocol and informed consent form to be patient-centered and “fit for purpose;” 3) Setting expectations for 100% retention; and 4) Using “site intelligence” to provide sites with preferred recruitment and retention tools. Authors: Erica Caveney, M.D., Vice President and Head, Diabetes Center of Excellence, Quintiles Tracy Stewart, MBA, Director, Global Biosimilars Unit, Quintiles Scott Oakes, Ph.D., Director, Clinical Project Management, Quintiles Kimberly Powers, Sr. Client Engagement Manager, Health Engagement & Communications,...
Explore More
White Paper
This white paper describes new approaches to developing more effective and sustainable therapies for RA and innovative ways to conduct RA clinical trials more efficiently, successfully demonstrating value to patients and key stakeholders.  Authors: Iain B. McInnes, PhD, FRSE, FMedSci, Muirhead Professor of Medicine and Director of the Institute of Infection, Immunity and Inflammation, University of Glasgow, Scotland Mary Katherine (MK) Farmer, MD, Therapeutic Strategy Lead, Rheumatology, Senior Medical Director, Immunology and Internal Medicine Therapeutic Delivery Unit, Quintiles Andrew Platt, PhD, Scientific Advisor, Global Central Laboratories,...
Explore More
White Paper
The year 2015 marks the 10th anniversary of the release of two ICH Harmonised Tripartite Guidelines that have governed the cardiac safety regulatory landscape, more specifically the proarrhythmic cardiac safety landscape, since their release in May 2005. ICH S7B addresses the non-clinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals, and ICH E14 addresses the clinical evaluation of QT interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, with a focus on the Thorough QT (TQT) Study. Our discussions in this paper focus on clinical evaluations. Authors: Snehal Kothari, MD, DM, FACC, FESC Dilip R. Karnad, MD, FACP, FRCP Gopi Krishna Panicker, BHMS, PGDCR J. Rick Turner,...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C. – February 25, 2015 – Quintiles announced today that it has been named to the 2015 CSO50 by IDG's CSO magazine in recognition of the company’s risk mitigation strategy managing Windows XP security challenges. CSO commended the Quintiles team for its innovative defense-in-depth model which minimized security risks for business-critical applications dependent on Windows XP, delivering secure and segmented platforms while protecting critical company assets. “This was an innovative solution to a problem that presents significant security concerns for many organizations around the world,” said Quintiles Chief Information Security Officer Patricia Collins Weedon. “Quintiles has launched many innovative customer solutions that require our team to think beyond current...
Read More
Scientific Poster
> read the full article that appeared in the Journal for Clinical...
Explore More
Press Release
RESEARCH TRIANGLE PARK, NC – February 24, 2015 – Quintiles today announced the appointment of Elgar Peerschke to serve as president, Advisory Services. In this role, Peerschke is responsible for leading Quintiles’ Advisory Services organization and the continued development and delivery of its related services. Bringing more than 25 years of experience to Quintiles, Elgar joins Quintiles from Bain & Company, a global business consulting firm, where he was a senior partner in its Global Healthcare Practice Group and a leading client service partner. Prior to Bain, Elgar spent more than a decade at McKinsey and Company in various leadership roles. “Throughout his career, Elgar has focused on the healthcare industry, providing cutting-edge insight and guidance in boardrooms of...
Read More
White Paper
Part two our three-part Executive Vision Forum White Paper discusses how biopharma can achieve innovations in medicine and remain competitive by preventing disease as opposed to reacting to it. This requires a proactive healthcare model - new technology, changes in the way we communicate with patients, and new structures to measure value and compensate physicians and pharma for the prevention solutions they...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C. – February 19, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for 2015. Quintiles is ranked third overall in FORTUNE’s Healthcare: Pharmacy and Other Services category with the top ranking for the reputation attribute of “global competitiveness” and second within the segment for its “people management.” FORTUNE's World's Most Admired Companies list is the definitive report card on corporate reputations. Since 1997, Fortune has identified, selected and ranked the World’s Most Admired Companies, uncovering the business practices that make these companies highly regarded among their peers. “I would like to congratulate Quintiles’ employees around the world for...
Read More
Fact Sheet
Genomics technology is transforming oncology treatment and drug development. The tools are now available to better understand the relationship between biomarkers and patient responses. Quintiles has developed the Quintiles Comprehensive Cancer Panel (QCCP), a targeted sequencing assay for analysis of genomic variation correlated with response to available therapeutics and with response to marketed and experimental therapies in clinical...
Read More